References
Jenner P: Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62(1 suppl 1):S47-S55.
Stocchi F, Olanow CW: Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 2004, 62(1 suppl 1):S56-S63.
Hutton JT, Metman LV, Chase TN, et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson’s disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov Disord 2001, 16:459–463.
Metman LV, Gillespie M, Farmer C, et al.: Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol 2001, 24:163–169.
Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 1989, 321:1364–1371.
Olanow CW, Calne D: Does selegiline monotherapy in Parkinson’s disease act by symptomatic or protective mechanisms? Neurology 1991, 42:13–26.
Parkinson Study Group: Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Parkinson Study Group. Ann Neurol 1998, 43:318–325.
Parkinson Study Group: Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000, 284:1931–1938.
Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002, 287:1653–1661.
Marek K, Seibyl J: Beta-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: long-term imaging assessment. Neurology 2003, 60(suppl 1):A293.
Ahlskog JE: Slowing Parkinson’s disease progression: recent dopamine agonist trials. Neurology 2003, 60:381–389.
Parkinson Study Group: Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial. Neurology 2003, 60(suppl 1):A80-A81.
Cervalo R, Piccini P, Bailey DL, et al.: 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse 2002, 43:201–207.
Turjanski N, Lees AJ, Brooks DJ: Striatal dopaminergic receptor dysfunction in patients with restless legs syndrome. 18Fdopa and 11C-raclopride PET studies. Neurology 1999, 52:932–937.
Rights and permissions
About this article
Cite this article
Morgan, J.C., Sethi, K.D. Ropinirole versus levodopa in parkinson’s disease. Curr Neurol Neurosci Rep 4, 274–276 (2004). https://doi.org/10.1007/s11910-004-0051-3
Issue Date:
DOI: https://doi.org/10.1007/s11910-004-0051-3